Literature DB >> 18752146

Mucosal cytokine imbalance in irritable bowel syndrome.

John Macsharry1, Liam O'Mahony, Aine Fanning, Emer Bairead, Graham Sherlock, Jay Tiesman, Andy Fulmer, Barry Kiely, Timothy G Dinan, Fergus Shanahan, Eamonn M M Quigley.   

Abstract

OBJECTIVE: To systematically examine mucosal biopsies for differences in cytokine gene expression and protein secretion.
MATERIAL AND METHODS: The study included 59 females with irritable bowel syndrome (IBS) and 39, otherwise healthy, female volunteers presenting for colonoscopy. Colonic biopsies from subsets were studied by microarray analysis (IBS, n=9; controls, n=8), quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (IBS, n=22; controls, n=21), and ex vivo biopsy culture (IBS, n=28, controls, n=10). Biopsies from patients with active colitis were used as inflammatory disease controls.
RESULTS: While gene array analysis revealed extensive overlapping between controls and IBS patients, reduced expression of genes linked to chemokine function was evident among the IBS patients alone. Differential expression was confirmed by qRT-PCR or ex vivo biopsy culture for 5 out of 6 selected genes. Reduced secretion of chemokines (IL-8, CXCL-9 and MCP-1) but not pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) was established on the basis of the ex vivo biopsy cultures. These findings were in marked contrast to the IBD patients who demonstrated increased production of both chemokines and pro-inflammatory cytokines.
CONCLUSIONS: Despite the expected heterogeneity of the disorder, differences in mucosal chemokine signalling were evident in this cross-sectional study of IBS patients at the level of both gene expression and protein secretion, with IBS patients demonstrating a consistent deficit in the expression and secretion of chemokines known to play a critical role in mucosal defence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752146     DOI: 10.1080/00365520802276127

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  56 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.

Authors:  Bin Feng; Jun Ho La; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 4.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

5.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

6.  The CCL28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms.

Authors:  Farshad Sheikhesmaili; Ali Jalili; Elmira Taghizadeh; Shohreh Fakhari; Khashaiar Jalili; Ebrahim Ghaderi; Ezatollah Rahimi
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

7.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

8.  From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome.

Authors:  Oscar Rodríguez-Fandiño; Joselín Hernández-Ruiz; Max Schmulson
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

Review 9.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

10.  Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome.

Authors:  Declan P McKernan; Aoife Nolan; Elizabeth K Brint; Siobhain M O'Mahony; Niall P Hyland; John F Cryan; Timothy G Dinan
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.